Suyash Prasad - Jul 5, 2022 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
CMO and Head of R&D
Signature
/s/ Kamran Alam, Attorney-in-Fact
Stock symbol
TSHA
Transactions as of
Jul 5, 2022
Transactions value $
-$47,650
Form type
4
Date filed
7/7/2022, 04:30 PM
Previous filing
Jul 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Sale -$13.7K -3.91K -0.72% $3.51* 540K Jul 5, 2022 Direct F1, F2
transaction TSHA Common Stock Sale -$33.9K -8.96K -1.66% $3.79* 531K Jul 6, 2022 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $4.00, inclusive.